Security Snapshot

Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) Institutional Ownership

CUSIP: 05156V102

13F Institutional Holders and Ownership History from Q3 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

253

Shares (Excl. Options)

71,981,811

Price

$15.95

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Shares, no par value
Symbol
AUPH on Nasdaq
Shares outstanding
132,929,348
Price per share
$14.82
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
71,981,811
Total reported value
$1,147,543,053
% of total 13F portfolios
0%
Share change
+4,822,729
Value change
+$82,901,917
Number of holders
253
Price from insider filings
$14.82
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value is tracked under CUSIP 05156V102.
  • 253 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 253 to 10 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,147,543,053 to $5,858,325.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 253 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 05156V102?
CUSIP 05156V102 identifies AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.2% 0% $170,846,115 12,229,500 0% TANG CAPITAL MANAGEMENT, LLC 23 Mar 2026
ILJIN SNT Co., Ltd. 5% $57,509,241 6,535,141 Chin Kyu Huh 11 Aug 2025
ARMISTICE CAPITAL, LLC 4.5% $51,840,000 6,400,000 Armistice Capital, LLC 31 Dec 2024

As of 31 Dec 2025, 253 institutional investors reported holding 71,981,811 shares of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH). This represents 54% of the company’s total 132,929,348 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) together control 40% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 8.5% 11,329,500 0% 8.9% $180,705,525
BlackRock, Inc. 6% 7,928,129 +6.4% 0% $126,453,658
NEA Management Company, LLC 3% 3,969,834 0% 3.2% $63,318,852
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.5% 3,387,194 +0.39% 0.03% $54,025,744
STATE STREET CORP 1.9% 2,501,992 -7.1% 0% $39,906,772
MORGAN STANLEY 1.7% 2,216,915 +14% 0% $35,359,797
TWO SIGMA INVESTMENTS, LP 1.5% 1,962,742 +46% 0.05% $31,305,735
RENAISSANCE TECHNOLOGIES LLC 1.2% 1,590,135 +9.7% 0.04% $25,362,653
MARSHALL WACE, LLP 1.2% 1,574,957 +6.2% 0.02% $25,120,564
D. E. Shaw & Co., Inc. 1.2% 1,532,273 +68% 0.02% $24,439,755
GEODE CAPITAL MANAGEMENT, LLC 1.1% 1,507,869 +1.5% 0% $24,046,973
VANGUARD GROUP INC 1.1% 1,449,884 -6.9% 0% $23,125,650
TWO SIGMA ADVISERS, LP 0.98% 1,305,800 +172% 0.04% $20,827,510
KOTLER KEVIN 0.92% 1,224,846 0% 14% $19,536,294
NOMURA HOLDINGS INC 0.87% 1,156,133 +266% 0.14% $18,440,321
JACOBS LEVY EQUITY MANAGEMENT, INC 0.86% 1,139,249 -6.6% 0.07% $18,171,022
GOLDMAN SACHS GROUP INC 0.76% 1,006,333 +20% 0% $16,051,011
JANE STREET GROUP, LLC 0.69% 910,737 +34% 0.02% $14,526,255
JUPITER ASSET MANAGEMENT LTD 0.68% 899,483 +9.2% 0.11% $14,346,754
Qube Research & Technologies Ltd 0.66% 874,345 -24% 0.02% $13,945,803
Man Group plc 0.64% 852,671 +369% 0.03% $13,600,103
NORTHERN TRUST CORP 0.6% 800,144 -11% 0% $12,762,297
CITADEL ADVISORS LLC 0.59% 779,495 +11% 0.01% $12,432,945
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.56% 739,444 +44% 0.04% $11,794,132
MILLENNIUM MANAGEMENT LLC 0.56% 738,306 +634% 0.01% $11,775,981

Institutional Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 394,103 $5,858,325 +$564,102 $14.82 10
2025 Q4 71,981,811 $1,147,543,053 +$82,901,917 $15.95 253
2025 Q3 65,698,350 $726,012,410 +$84,257,823 $11.05 240
2025 Q2 58,318,900 $494,168,918 -$31,810,462 $8.47 216
2025 Q1 62,001,205 $498,579,335 +$33,892,897 $8.04 210
2024 Q4 57,799,592 $519,061,476 +$4,097,220 $8.98 197
2024 Q3 57,639,569 $422,207,215 +$21,955,759 $7.33 180
2024 Q2 55,307,620 $315,754,570 +$4,958,367 $5.71 168
2024 Q1 54,674,386 $273,920,542 +$3,860,760 $5.01 173
2023 Q4 53,220,649 $478,436,427 +$38,734,205 $8.99 186
2023 Q3 50,339,448 $391,141,750 -$739,167 $7.77 194
2023 Q2 49,820,766 $482,543,239 -$1,739,141 $9.68 197
2023 Q1 49,994,676 $547,934,449 +$7,051,204 $10.96 182
2022 Q4 51,117,260 $220,815,199 -$24,246,473 $4.32 181
2022 Q3 55,353,711 $416,255,629 +$28,431,118 $7.52 177
2022 Q2 50,117,033 $503,590,633 +$74,385,031 $10.05 191
2022 Q1 42,164,731 $521,893,499 +$1,302,371 $12.38 176
2021 Q4 38,512,517 $881,056,850 -$105,784,806 $22.87 180
2021 Q3 43,124,514 $954,392,864 -$114,507 $22.13 160
2021 Q2 49,010,949 $635,371,815 -$42,000,595 $12.96 162
2021 Q1 52,072,235 $676,156,911 -$80,619,096 $12.99 163
2020 Q4 57,920,959 $801,022,755 -$114,549,555 $13.83 139
2020 Q3 64,784,594 $954,040,391 +$75,038,433 $14.73 144
2020 Q2 58,637,850 $953,206,339 -$24,791,270 $16.25 127
2020 Q1 60,307,130 $875,021,915 +$158,173,274 $14.51 122
2019 Q4 48,880,484 $990,406,662 +$509,187,869 $20.26 110
2019 Q3 25,474,542 $136,035,080 -$23,251,716 $5.34 68
2019 Q2 29,347,880 $193,099,929 -$3,061,002 $6.58 71
2019 Q1 29,823,940 $193,853,541 +$49,275,242 $6.50 76
2018 Q4 22,212,575 $151,471,995 +$3,053,577 $6.82 59
2018 Q3 21,500,016 $144,548,400 +$1,928,619 $6.64 62
2018 Q2 21,282,120 $121,759,408 -$2,409,149 $5.63 65
2018 Q1 21,720,891 $112,732,308 -$10,024,771 $5.19 63
2017 Q4 23,825,802 $107,940,708 -$515,812 $4.53 66
2017 Q3 23,438,674 $146,961,556 +$2,094,667 $6.27 59
2017 Q2 23,175,243 $142,270,544 -$8,837,055 $6.13 64
2017 Q1 23,813,237 $174,794,651 +$114,421,765 $7.34 71
2016 Q4 8,627,972 $18,126,000 +$8,662,521 $2.10 22
2016 Q3 4,238,270 $12,814,000 -$8,129,564 $3.01 14
2016 Q2 7,070,693 $20,093,000 +$878,266 $2.78 13
2016 Q1 6,743,443 $19,673,000 +$25,044 $2.92 16
2015 Q4 6,732,938 $16,753,741 -$1,105,844 $2.47 14
2015 Q3 7,110,273 $20,112,000 -$538,914 $2.84 11
2015 Q2 7,222,335 $21,748,000 -$1,342,201 $3.02 13
2015 Q1 7,607,904 $33,247,000 -$3,826,120 $4.37 11
2014 Q4 8,484,410 $30,665,000 +$8,984,489 $3.61 9
2014 Q3 6,016,277 $19,267,000 +$19,267,000 $3.20 8

Sponsored